PSME2 and breast carcinoma: A recently reported PSME2 Proteasome activator complex subunit 2 was positively correlated with immunomodulators, tumor mutation burden (TMB) levels, tumor-infiltrating immune cells (TIICs), and immune checkpoints in breast cancer tissue [29], and it was also associated with the invasion ability of clear cell renal cell carcinoma by inhibiting BNIP3-mediated autophagy [30].